The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ramifications for both mother and offspring from pregnancy into later life. Also contentious are the outcomes of intervention with diet, insulin, glyburide (Glynase trade mark, Pharmacia Upjohn) and metformin (Glucophage trade mark, Bristol-Myers Squibb). There is consensus that women with unequivocal GD have a significant risk of adverse perinatal outcomes and increased risk of later type 2 diabetes mellitus. Foetuses from pregnancies with GD have a higher risk of macrosomia (associated with higher rate of birth injuries), asphyxia, and neonatal hypoglycaemia and hyperinsulinaemia. Uncontrolled GD predisposes foetuses to accelerated, excessive fat accumulation, insulin resistance, pancreatic exhaustion secondary to prenatal hyperglycaemia and possible higher risk of child and adult obesity and type 2 diabetes mellitus later in adult life. However, there is no consensus as to whether glucose intolerance of a severity below unequivocal GD is related to adverse maternal, fetal or perinatal outcomes, and whether this relationship is a continuous one. If dietary intervention is not sufficient in the treatment of GD, then, historically, insulin has been added. Recent studies suggest that glyburide may be efficaciously substituted for insulin. Preliminary studies suggest that metformin may have the unique potential to prevent the development of GD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“[46] have shown that 31% of obese women with PCOS have impaired glucose tolerance, 7.”
BackgroundLillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“The prevalence of impaired glucose tolerance and type 2 DM in PCOS is much higher than in age- and weight-matched women without PCOS [49].”
BackgroundFranz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 4×
“Cord serum insulin levels did not differ by treatment group; glyburide was not detected in the cord serum [92].”
BackgroundMethodInfluentialCarbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus
Butte, N. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1256s · Cited by 826
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Cited by
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Metformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
“When an appropriate diet, alone or associated with physical exercise, does not suffice to control blood glucose levels in pregnant women, subcutaneous insulin therapy has been considered the standard for management of GDM [12-14].”
BackgroundGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Self-citation
Metadata
- Authors
- Glueck, C. J., Goldenberg, N., Streicher, P., & Wang, P.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2002-11
- Volume
- 3
- Issue
- 11
- Pages
- 1557-1568
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2069657814
- Cited by
- 38
- References
- 25
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. https://app.cochat.ai/papers/10.1517/14656566.3.11.1557
- The paper
- Glueck, C. J., Goldenberg, N., Streicher, P., & Wang, P. (2002). The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.3.11.1557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.